Learn with Anil · UPSC Civil Services PYQsMains PYQs →Subscribe ₹149
INS Vikrant and INS Vikramaditya sailing with their carrier battle group

Photo: INS Vikrant and INS Vikramaditya, Indian Navy, GODL-India

UPSC Civil Services (Main) 2022 · GS Paper III

UPSC Mains 2022 GS 3 · Q16: model answer

General Studies Paper III: Technology, Economic Development, Bio-diversity, Environment, Security and Disaster Management · Science and Technology.

Q1615 marks250 words2022 · GS Paper III

What is the basic principle behind vaccine development? How do vaccines work? What approaches were adopted by the Indian vaccine manufacturers to produce COVID-19 vaccines?

Syllabus: Science and Technology · Biotechnology and health technology

Model answer · free

VaccineActive immunityImmunological memoryVaccine platforms

A vaccine is a biological preparation that trains the immune system to recognise a pathogen without causing the disease, producing active immunity and lasting immunological memory. Since Edward Jenner's smallpox vaccine (1796), vaccines have eradicated smallpox and nearly eliminated polio. India, which makes nearly 60% of the world's vaccines, developed and produced several COVID-19 vaccines on different platforms.

1. Basic principle of vaccine development

  • Mimic infection safely: present an antigen (a killed or weakened microbe, one of its proteins, or the genetic code for that protein) so that the immune system responds as it would to infection.
  • Choose the right antigen: most COVID-19 vaccines targeted the spike protein, which SARS-CoV-2 uses to enter human cells.
  • Boost the response: adjuvants such as alum strengthen and prolong immunity.
  • Prove safety and efficacy: laboratory and animal studies, then Phase I (safety), Phase II (dose and immune response) and Phase III (efficacy in large groups) trials, licensing by the regulator (CDSCO in India) and post-marketing surveillance.
  • Scale and stability: the vaccine must be mass-produced and stay stable in a cold chain, often at 2–8 °C.

2. How vaccines work

  • Antigen presentation: dendritic cells and other antigen-presenting cells take up the antigen and display it to helper T cells.
  • Antibodies: activated B cells produce antibodies that neutralise the virus and block its entry into cells.
  • Cell-mediated immunity: cytotoxic (killer) T cells learn to destroy infected cells.
  • Memory: memory B and T cells persist, so a later infection meets a fast, strong response that prevents severe disease.
  • Herd immunity: when enough people are immune, transmission falls and the vulnerable are protected.
Vaccine antigen enters the body
Dendritic cells present it to helper T cells
B cells make antibodies; killer T cells are primed
Memory B and T cells persist
Real infection is stopped quickly
How a vaccine protects the body

3. Approaches adopted by Indian manufacturers

ApproachVaccine and makerKey feature
Inactivated whole virusCovaxin (Bharat Biotech with ICMR-NIV)Virus isolated in India, grown and killed
Viral vectorCovishield (Serum Institute; Oxford-AstraZeneca design)Harmless chimpanzee adenovirus carries the spike gene
Nasal viral vectoriNCOVACC (Bharat Biotech)India's first nasal COVID-19 vaccine
DNAZyCoV-D (Zydus)World's first human DNA vaccine (2021); needle-free
Protein subunitCorbevax (Biological E)Receptor-binding part of the spike, made in yeast
mRNAGEMCOVAC (Gennova)India's first mRNA vaccine; kept at 2–8 °C
Indian COVID-19 vaccines and their platforms
  • Indigenous development: Covaxin used a virus strain isolated by ICMR's National Institute of Virology, Pune; ZyCoV-D and GEMCOVAC built new DNA and mRNA platforms at home.
  • Partnerships and scale: licensing global designs (Oxford-AstraZeneca for Covishield, Novavax for Covovax, Sputnik V with Dr. Reddy's) and using India's large manufacturing base.
  • Government support: Mission COVID Suraksha (₹900 crore, 2020) through the Department of Biotechnology and BIRAC, emergency-use approvals, parallel trials and production, and the CoWIN platform; over 220 crore doses were given, and vaccines went abroad under Vaccine Maitri.

India's COVID-19 experience showed the value of multiple vaccine platforms, strong manufacturing and public research. Investing in mRNA, DNA and other new platforms now is the best preparation for the next pandemic.

Every model answer here is free

The ₹149 All-in-One Pass opens the rest of the site for 12 months: UPSC Prelims GS Paper I and CSAT with explanations, practice quizzes and timed tests, UPSC CAPF and EPFO, the previous papers of every APPSC, TSPSC, police and SSC exam, every mock test series and the study books.

₹149 · valid for 12 months from the day you pay, on every exam · pay by UPI, card or net banking

Get it for ₹149